

Halamid® Aqua (Chloramine-T) Approval

Axcentive SARL (headquartered in France) announced yesterday that the U.S. Food and Drug Administration Center for Veterinary Medicine has awarded a New Animal Drug Application (NADA) approval for Halamid® Aqua (100% chloramine-T). This is a HUGE milestone for collaborative efforts between public and private-sector partners to obtain new FDA-approved drugs for use in aquatic species. Halamid® Aqua is the 2nd waterborne drug approved for disease claims for finfish in almost 30 years, and is the 3rd new aquaculture drug with an original approval covering multiple claims for use in a variety of finfish species.

HALAMID® Aqua can be used to control mortality in:

- Freshwater-reared salmonids due to bacterial gill disease at a dosage of 12—20 mg chloramine-T/L administered for 60 min daily in a static or flow through bath on three consecutive or alternate days,
- Walleye and all freshwater-reared warm water finfish due to external columnaris disease at a dosage of 20 mg chloramine-T/L administered for 60 min daily in a static or flow through bath on three consecutive or alternate days

The approval of HALAMID® Aqua is the result of coordinated efforts between Axcentive SARL and public sector partners, including the Association of Fish and Wildlife Agencies, USFWS Aquatic Animal Drug Approval Partnership Program, USGS Upper Midwest Environmental Sciences Center, and the National NADA Coordinator (currently Roz Schnick Consulting, LLC).

HALAMID® Aqua will be distributed by Western Chemical, Inc. (Ferndale, Washington) and is available in 5 kg buckets or 25 kg drums

More detailed information can be found at the Axcentive website (www.axcentive.com/), the Western Chemical, Inc. website (www.wchemical.com/), and the FDA webpage of approved aquaculture drugs (www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/Aquaculture/ucm132954)

Mention of trade names or commercial products does not imply recommendations or endorsements by the U.S. Fish and Wildlife Service or the Aquatic Animal Drug Approval Partnership Program.